GlassScriptPhysician profile
Tess Chamakkala
NPI 1326530668
$6,805.98
in general payments reported to CMS, 2019-2025
47 companies · $3,024 in 2025
The $3,024 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2023: $570 · 2024: $3,090 · 2025: $3,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,588 · Education: $96.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,587.63 |
| Education | $96.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $697.76 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Corcept Therapeutics | $606.97 | 2023-2025 | Korlym |
| Cequr Corporation | $469.37 | 2024-2025 | Cequr Simplicity |
| Novartis Pharmaceuticals Corporation | $425.20 | 2023-2025 | |
| Mannkind Corporation | $411.01 | 2023-2025 | Afrezza |
| Novo Nordisk INC | $358.60 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Insulet Corporation | $311.20 | 2023-2025 | Omnipod |
| Amgen INC. | $275.32 | 2024-2025 | Evenity, Tepezza, Repatha |
| Astellas Pharma US INC | $268.18 | 2023-2025 | Veozah |
| Tandem Diabetes Care, INC. | $264.19 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $208.33 | 2023-2025 | |
| Amphastar Pharmaceuticals, INC. | $183.70 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $177.72 | 2023-2025 | |
| Sequel Med Tech, LLC | $177.72 | 2025 | Twiist |
| Dexcom, INC. | $172.40 | 2023-2025 | Dexcom G6 Transmitter |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $146.48 | 2019-2024 | Spravato |
| Recordati_rare_diseases_inc. | $132.79 | 2023-2025 | Isturisa, Signifor Lar |
| Esperion Therapeutics, INC. | $121.84 | 2024-2025 | Nexletol |
| Madrigal Pharmaceuticals | $117.18 | 2025 | Rezdiffra |
| Radius Health, INC. | $114.23 | 2023-2025 | Tymlos |
| Xeris Pharmaceuticals, INC. | $110.68 | 2024-2025 | Gvoke Hypopen |
| Ibsa Pharma INC. | $97.38 | 2023-2024 | Tirosint, Tirosint, Licart |
| Kyowa Kirin, INC. | $74.34 | 2024 | Crysvita |
| Averitas Pharma INC. | $69.23 | 2024 | Qutenza |
| Antares Pharma, INC. | $68.87 | 2024 | Xyosted |
| Amneal Pharmaceuticals LLC | $65.71 | 2024 | Unithroid |
| Alexion Pharmaceuticals, INC. | $63.43 | 2023-2025 | Strensiq |
| Corium, LLC | $62.96 | 2024-2025 | Azstarys |
| Verity Pharmaceuticals INC. | $58.70 | 2024 | Tlando |
| Ascendis Pharma Endocrinology INC | $52.25 | 2025 | Yorvipath |
| Tolmar, INC. | $44.14 | 2024-2025 | Jatenzo |
| Beta Bionics, INC. | $41.76 | 2024 | Ilet Bionic Pancreas |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.96 | 2023-2025 | Jardiance |
| Abbvie INC. | $33.48 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.42 | 2025 | Caplyta |
| Embecta Corp. | $28.40 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Abbott Laboratories | $24.08 | 2024 | Freestyle Libre 3 |
| Brainsway USA INC | $23.97 | 2024 | Brainsway Deep Tms System |
| Echosens North America, INC. | $23.78 | 2025 | Fibroscan |
| Theracosbio, LLC | $21.71 | 2024 | Brenzavvy |
| Boston Scientific Corporation | $21.39 | 2025 | General - Pain Management |
| Chiesi USA, INC. | $20.87 | 2024 | Myalept |
| Halozyme INC | $20.77 | 2023 | |
| Pfizer INC. | $20.58 | 2024 | |
| Alvogen INC | $16.49 | 2025 | Teriparatide |
| Neurocrine Biosciences, INC. | $16.31 | 2025 | |
| Supernus Pharmaceuticals, INC. | $16.13 | 2025 | Tlando, Xyosted, Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tess Chamakkala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.